This company develops precision therapeutics by engineering chemokines to modulate immune system pathways in oncology and immunology. Their platform focuses on enhancing specificity and reducing off-target effects in drug candidates. The goal is to unlock new therapeutic possibilities across various disease areas using targeted chemokine biology.
Funding
$100K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current chemokine-targeted therapies often lack precision, leading to off-target effects and limited efficacy in treating diseases driven by cell migration. This is due to the challenges in selectively modulating chemokine activity without causing broad immune suppression. As a result, there is a need for more targeted approaches to inhibit harmful cell migration in cancer metastasis and autoimmune diseases.
Solution
XLock BioSciences is developing a new class of biologics based on protein engineering to create highly selective chemokine-targeted therapies. Their approach focuses on designing molecules that precisely modulate chemokine activity, overcoming the limitations of current treatments. By targeting specific chemokine-receptor interactions, XLock's molecules aim to inhibit deleterious cell migration associated with cancer metastasis and autoimmune disorders, while minimizing off-target effects and avoiding general immune system suppression. Their lead molecules target the CCR6/CCL20 pathway for TH-17 driven autoimmune diseases and the CXCR4/CXCL12 pathway to prevent cancer spread.
Target Audience
The primary target audience includes patients with TH-17 driven autoimmune diseases, such as psoriasis, and cancer patients at risk of metastasis.
Features
- Protein engineering platform for creating chemokine-targeted therapeutics
- Selective modulation of chemokine activity to minimize off-target effects
- Lead molecule CCL20LD/XL106 targeting the CCR6/CCL20 pathway
- Lead molecule targeting the CXCR4/CXCL12 pathway
- Designed to avoid general immune system suppression
- Potential to prevent the production of anti-drug antibodies